These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 16322266)

  • 1. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts.
    Lee J; Fassnacht M; Nair S; Boczkowski D; Gilboa E
    Cancer Res; 2005 Dec; 65(23):11156-63. PubMed ID: 16322266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J; Brück J; Lenz J; Knop J; Tüting T
    Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma.
    O-Sullivan I; Kim TS; Chopra A; Cohen EP
    Anticancer Res; 2006; 26(2A):873-84. PubMed ID: 16619482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
    Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
    Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-specific crosslinking of GITR as costimulation for immunotherapy.
    Burckhart T; Thiel M; Nishikawa H; Wüest T; Müller D; Zippelius A; Ritter G; Old L; Shiku H; Renner C
    J Immunother; 2010; 33(9):925-34. PubMed ID: 20948444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells.
    Asavaroengchai W; Kotera Y; Koike N; Pilon-Thomas S; Mulé JJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):524-33. PubMed ID: 15282530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical implications of fibroblast activation protein in patients with colon cancer.
    Henry LR; Lee HO; Lee JS; Klein-Szanto A; Watts P; Ross EA; Chen WT; Cheng JD
    Clin Cancer Res; 2007 Mar; 13(6):1736-41. PubMed ID: 17363526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model.
    Cheng JD; Dunbrack RL; Valianou M; Rogatko A; Alpaugh RK; Weiner LM
    Cancer Res; 2002 Aug; 62(16):4767-72. PubMed ID: 12183436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
    Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells.
    Preynat-Seauve O; Contassot E; Schuler P; French LE; Huard B
    Melanoma Res; 2007 Jun; 17(3):169-76. PubMed ID: 17505262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined dendritic cell cryotherapy of tumor induces systemic antimetastatic immunity.
    Machlenkin A; Goldberger O; Tirosh B; Paz A; Volovitz I; Bar-Haim E; Lee SH; Vadai E; Tzehoval E; Eisenbach L
    Clin Cancer Res; 2005 Jul; 11(13):4955-61. PubMed ID: 16000595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
    Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
    Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A DNA vaccine targeting Fos-related antigen 1 enhanced by IL-18 induces long-lived T-cell memory against tumor recurrence.
    Luo Y; Zhou H; Mizutani M; Mizutani N; Liu C; Xiang R; Reisfeld RA
    Cancer Res; 2005 Apr; 65(8):3419-27. PubMed ID: 15833877
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity.
    Nair S; Boczkowski D; Fassnacht M; Pisetsky D; Gilboa E
    Cancer Res; 2007 Jan; 67(1):371-80. PubMed ID: 17210720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
    Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
    Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.